Symbiotic Capital Life Science Credit Parallel Fund, L.P.

The absence of any prior EDGAR filings from this manager indicates Symbiotic Capital is making its first formal fund filing to the SEC, which combined with the five named GPs (including founder Arie Belldegrun, a known biotech investor) signals a newly-formalized or newly-registered fund complex rather than an established series — allocators should treat this as a first-time institutional raise despite any track record the GPs may hold individually.

Filing an amendment in May 2026 for a life science credit fund reflects positioning ahead of anticipated exits and refinancings in biotech debt portfolios accumulated during the 2023–2025 period, when life science financing tightened and credit became a primary capital source for drug development companies.

Before committing, verify whether the five named GPs include a single key person whose departure would trigger buyout clauses or fund termination rights, and confirm whether this parallel fund has its own management fee and carry structure or piggybacks on the main fund's economics — these details materially affect LP returns and risk exposure.